Neurocrine Biosciences
NBIX
$199.40
Share price
-0.39%
Change (1 day)
-13.31%
Change (1 year)
Categories
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.
Neurocrine Biosciences (NBIX) Fails to deliver data
Key failure to deliver metrics for Neurocrine Biosciences :
- Last SEC data release: 2025-02-28
- Last 15 days FTD volume: NZ$0.23 M
- Last 3 months FTD volume: NZ$8.23 M
- Last year FTD volume: NZ$8.23 M
A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.
Failures to deliver for Neurocrine Biosciences (NBIX) - 3 months history
Number of shares, 3 months chart
Biweekly Failures to deliver volume for Neurocrine Biosciences (NBIX) - since 2013
Volume in USD (price x number of shares), data since 2013Neurocrine Biosciences (NBIX) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2025 | NZ$7.74 M | -68.51% |
| 2024 | NZ$24.58 M | 12.15% |
| 2023 | NZ$21.91 M | -32.24% |
| 2022 | NZ$32.34 M | -26.75% |
| 2021 | NZ$44.16 M | 193.08% |
| 2020 | NZ$15.06 M | -65.24% |
| 2019 | NZ$43.34 M | -3.16% |
| 2018 | NZ$44.76 M | -18.56% |
| 2017 | NZ$54.96 M | 78.43% |
| 2016 | NZ$30.8 M | 53.41% |
| 2015 | NZ$20.07 M | 66.9% |
| 2014 | NZ$12.03 M | 241.08% |
| 2013 | NZ$3.52 M |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3 months) | FTD volume (1 year) | Country |
|---|---|---|---|
 | NZ$5.06 M | NZ$34.3 M | 🇺🇸 USA |
 | NZ$33.94 M | NZ$42.91 M | 🇬🇧 UK |
 | NZ$2.37 M | NZ$4.19 M | 🇺🇸 USA |
 | NZ$67.4 M | NZ$0.23 B | 🇺🇸 USA |
 | NZ$45.77 M | NZ$0.20 B | 🇺🇸 USA |
 | NZ$29.94 M | NZ$0.34 B | 🇺🇸 USA |
 | NZ$2.3 M | NZ$4.43 M | 🇺🇸 USA |
 | NZ$0.09 M | NZ$0.71 M | 🇺🇸 USA |